2Godwin J E, Kopecky K J, Head D R, et al. A doubleblind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreatedacute myeloid leukemia:a Southwest Oncology Group study. Blood, 1998, 91:3607-3615. 被引量：1
3Leith C P, Kpecky K J, Godwin J, et al. Acute myeloid leukemia in the elderly:a ssessment of multigrug resistance (MDR-1)and cytogenenties distinguishes biologic subgroups with remarkable distinct responses to standard chemotherapy: a Southwest Oncology G 被引量：1
4Cassileth P A, Harrington D P, Appelbaum F R, et al. Chemotherapu compared with autologous or allogenenic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med, 1998, 339:1649-1656. 被引量：1
5Estey E. Treatment of refractory AML. Leukemia, 1996, 10:932-932. 被引量：1
6HIddeman W, Kern W, Schoch C, et al. Management of acute myeloid leukemia in elderly patients. J Clin Onc, 1999, 17:3569-3576. 被引量：1
7Benzin J, Lang K, Earle C C, et al. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Inter Med, 2002, 22:162:1597-1603. 被引量：1
8Lyman CH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving doseintensive cancer chemotherapy: a meta-analysis [ J ]. Am J med,2002,113:766 - 768. 被引量：1
9Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplatation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases[ J]. Blood, 1998,91:756 - 763. 被引量：1
